Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial.

Cureus · 2023 · PMC10162885 · PMID 37153322

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

fairly significantno p-value reported

The patient experienced fairly significant re-pigmentation and reported around 70% improvement on 11 months of treatment with apremilast at 30mg twice daily and two shots of 60mg triamcinolone, first at three months a repeat shot at 4.5 months of treatment [ 16 ].

also in 163 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.